PCSA Stock Analysis: Buy, Sell, or Hold?
PCSA - Processa Pharmaceuticals, Inc. Common
$1.81
-0.05 (-2.69%)
âŧ
5d:
+7.1%
30d:
-2.16%
90d:
-30.12%
WAIT
LOW Confidence
Analysis Updated: Oct 23, 2026 12:00 AM ET
Earnings: Nov 05, 2026
11d
Get Alerted When PCSA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: PCSA is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: PCSA is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: PCSA is currently trading at $1.81, which is considered fair relative to its 30-day fair value range of $1.58 to $1.90.
Technical Outlook: Technically, PCSA is in a downtrend. Immediate support is located at $1.50, while resistance sits at $1.98.
Market Sentiment: PCSA scores 16/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $25.00 (+1281.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, PCSA is in a downtrend. Immediate support is located at $1.50, while resistance sits at $1.98.
Market Sentiment: PCSA scores 16/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $25.00 (+1281.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$1.58 -
$1.90
Company Quality Score
31/100
(SELL)
Volume Confirmation
MODERATE
Confidence Score
44.7%
All Signals
- NEUTRAL: Price in fair range
- BEARISH: Weak technical setup (16/100)
- BULLISH: Trading 1281.2% below Wall St target ($25.00)
- WARNING: Composite score 30/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$1.58 -
$1.90
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$1.50
Resistance Level
$1.98
Current Trend
Downtrend
Technical data as of
Oct 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.48
Wall Street Target
$25.00
(+1281.2%)
Share & Embed Analysis
Last updated: October 24, 2026 5:39 AM ET
Data refreshes hourly during market hours. Next update: 6:39 AM
Data refreshes hourly during market hours. Next update: 6:39 AM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PCSA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
INSM
Insmed Inc |
STRONG BUY
24 analysts |
$197 | 53 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
22 analysts |
$109 | 64 BUY |
|
MDGL
Madrigal PharmaceuticalsâĻ |
STRONG BUY
19 analysts |
$686 | 48 HOLD |
|
IMNM
Immunome Inc |
STRONG BUY
16 analysts |
$35 | 59 HOLD |
|
CGON
CG Oncology, Inc. CommonâĻ |
STRONG BUY
15 analysts |
$91 | 64 BUY |
